>
Switch to:

Biomarin Pharmaceutical Scaled Net Operating Assets

: 0.72 (As of Sep. 2021)
View and export this data going back to 1999. Start your Free Trial

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biomarin Pharmaceutical's operating assets for the quarter that ended in Sep. 2021 was $4,898 Mil. Biomarin Pharmaceutical's operating liabilities for the quarter that ended in Sep. 2021 was $624 Mil. Biomarin Pharmaceutical's Total Assets for the quarter that ended in Jun. 2021 was $5,898 Mil. Therefore, Biomarin Pharmaceutical's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2021 was 0.72.


Biomarin Pharmaceutical Scaled Net Operating Assets Historical Data

The historical data trend for Biomarin Pharmaceutical's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Scaled Net Operating Assets
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.64 0.59 0.73 0.88

Biomarin Pharmaceutical Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Scaled Net Operating Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.67 0.71 0.73 0.73

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biomarin Pharmaceutical Scaled Net Operating Assets Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Scaled Net Operating Assets falls into.



Biomarin Pharmaceutical Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Biomarin Pharmaceutical's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2020 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2020 )
=(Operating Assets (A: Dec. 2020 )-Operating Liabilities (A: Dec. 2020 ))/Total Assets (A: Dec. 2019 )
=(4782.634-655.119)/4690.039
=0.88

where

Operating Assets(A: Dec. 2020 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5848.02 - 1065.386
=4782.634

Operating Liabilities(A: Dec. 2020 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1742.018 - 1075.145 - 11.754
=655.119

Biomarin Pharmaceutical's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2021 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2021 )
=(Operating Assets (Q: Sep. 2021 )-Operating Liabilities (Q: Sep. 2021 ))/Total Assets (Q: Jun. 2021 )
=(4897.999-623.574)/5898.496
=0.72

where

Operating Assets(Q: Sep. 2021 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=5977.475 - 1079.476
=4897.999

Operating Liabilities(Q: Sep. 2021 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=1711.326 - 1078.093 - 9.659
=623.574

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)